Imaging features of ocular adnexal lymphoproliferative disease

Eye

Volumn 20, Issue 10, 2006, Pages 1189-1195

  Sullivan, T J ^a,b   Valenzuela, A A ^a  

^a ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

CT; Gallium; Lymphoma; MRI; Ocular adnexa; PET

Indexed keywords

GADOLINIUM; GALLIUM;

ADOLESCENT; ADULT; AGED; BONE DESTRUCTION; COHORT ANALYSIS; COMPUTER ASSISTED TOMOGRAPHY; CONFERENCE PAPER; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DIAGNOSTIC IMAGING; EYE DISEASE; FEMALE; HISTOPATHOLOGY; HUMAN; IMAGE ANALYSIS; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT CARE; POSITRON EMISSION TOMOGRAPHY; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; SCHOOL CHILD; SCINTISCANNING; SENSITIVITY AND SPECIFICITY; SIGNAL PROCESSING;

EID: 33749482926     PISSN: 0950222X     EISSN: 14765454     Source Type: Journal    
DOI: 10.1038/sj.eye.6702382     Document Type: Conference Paper

References (39)

1. Yeo JH, Jakobiec FA, Abbott GF, Trokel SL. Combined clinical and computed tomographic diagnosis of orbital lymphoid tumors. Am J Ophthalmol 1982; 94(2): 235-245.
2. Weber AL, Dallow RL, Oot RF. CT evaluation of lymphoproliferative disease of the orbit in fifty patients. In: Greitz T (ed). Thirteenth symposium Neuroradiologicum. Stockholm, June 23-28, 1986. Stockholm: Acta Radiol Suppl; 1987.
3. Flanders AE, Espinosa GA, Markiewicz DA, Howell DD. Orbital lymphoma. Role of CT and MRI. Radiol Clin North Am 1987; 25(3): 601-613.
4. Westacott S, Garner A, Moseley IF, Wright JE. Orbital lymphoma vs reactive lymphoid hyperplasia: An analysis of the use of computed tomography in differential diagnosis. Br J Ophthalmol 1991; 75(12): 722-725.
5. Chisin R, Weber AL. Imaging of lymphoma manifestations in the extracranial head and neck region. Leuk Lymphoma 1994; 12(3-4): 177-189.
6. Polito E, Galieni P, Leccisotti A. Clinical and radiological presentation of 95 orbital lymphoid tumors. Graefes Arch Clin Exp Ophthalmol 1996; 234(8): 504-509.
7. De Potter P, Dolinskas C, Shields CL, Shields JA. Lymphoproliferative and histiocytic disorders. In: De Potter P, Shields JA, Shields CL (eds). MRI of the eye and orbit. J.B. Lippincott: Philadelphia, 1995, pp 245-247.
8. Chan JKC, Banks PM, Cleary ML et al. A proposal for classification of lymphoid neoplasms (by the International Lymphoma Study Group). Histopathology 1994; 25: 517-536.
9. Chan JK, Banks PM, Cleary ML et al. A revised European-Americal classification of lymphoid neoplasms by the International Lymphoma Study Group. A summary version. Am J Clin Pathol 1995; 103: 543-560.
10. Jaffe ES, Harris NL, Diebold J, Muller-Hermelink H-K. World Health Organisation classification of neoplastic diseases of the hematopoietic and lymphoid tissues. Am J Clin Pathol 1999; 111(Suppl): S8-S12.
11. Sullivan TJ, Whitehead K, Williamson R, Grimes D, Schlect D, Brown I et al. Lymphoproliferative disease of the ocular adnexae: A clinical and pathological study with statistical analysis of 69 patients. Ophthal Plast Reconstr Surg 2005; 21: 177-188.
12. Henderson JW. Hemotopoietic tumors. In: Henderson JW (ed). Orbital Tumors, 3rd ed. Raven Press: New York, 1994, pp 279-307.
13. Shileds JA, Saunders WB. Lymphoid tumors and leukemias. In: Shileds JA, Saunders WB (eds). Diagnosis and management of orbital tumors. J.B. Lippincott: Philadelphia, 1989, pp 316-340.
14. Bilanjuk LT, Zimmerman RA, Newton TH. Magnetic resonance imaging. Orbital pathology. In: Newton TH, Bilaniuk LT (eds). Radiology of the eye and orbit. Raven Press: New York, 1990, pp 5.1-5.84.
15. Flanders AE, Espinosa GA, Markiewicz DA, Howell DD. Orbital lymphoma: role of CT and MRI. Radiol Clin North Am 1987; 25: 601-614.
16. Gunasekera SW, King LJ, Lavender PJ. The behaviour of tracer gallium-67 towards serum proteins. Clin Chim Acta 1972; 2: 401-406.
17. Wong H, Terner UK, English D, Noujaim AA, Lentle BC, Hill JR. The role of transferrin in the in vivo uptake of gallium-67 in a canine tumor. Int J Nucl Med Biol 1980; 7: 9-16.
18. Anghileri LJ. Cell membrane permeability and tumor scanning agents: facts and possibilities. J Nucl Med Allied Sci 1978; 22: 101-103.
19. Muranka A, Ito Y, Hashimoto M et al. Uptake and excretion of 67-Ga-citrate in malignant yumors and normal cells. Eur J Nucl Med 1980; 5: 31-37.
20. Brown DH, Swartzendruber DC, Carlton JE, Byrd BL. The isolation and characterization of gallium-binding granules from soft tissue tumors. Cancer Res 1973; 33: 2063-2067.
21. Hayes RL, Carlton JE. A study of macromolecular binding of 67-Ga-citrate in normal and malignant tissues. Cancer Res 1973; 33: 3265-3272.
22. Johnson GS, Go MF, Benua RS et al. Gallium-67-citrate imaging in Hodkin's disease:fInal report of coorperative group. J Nucl Med 1977; 18: 692-698.
23. Andrews GA, Hubner KF, Greenlaw RH. Ga-67 citrate imaging in malignant lymphoma. J Nucl Med 1978; 19: 1013-1019.
24. Bekerman C, Szidon JP, Pinsky S. The role of gallium-67 in the clinical evaluation of sarcoidosis. Semin Roentgenol 1985; 20: 400-409.
25. Anderson KC, Leonard RC, Canellos GP, Skarin A, Kaplan WD. High-dose gallium imaging in lymphoma. AM J Med 1983; 75: 327-331.
26. Front D, Israel O, Epelbaum R, Ben Haim S, Sapir ES, Jerushalmi J et al. Ga-67 SPECT before and after treatment of lymphoma. Radiology 1990; 175: 515-519.
27. Tumeh SS, Rosenthal DS, Kaplan WD, English RJ, Holman BL. Lymphoma: evaluation with Ga-67 SPECT. Radiology 1987; 164: 111-114.
28. Weber G. Biochemical strategy of cancer cells and the design of chemotherapy. GHA Clowes memorial lecture. Cancer 1983; Res 43: 3466-3492.
29. Bar-Shalom R, Valdivia AY, Balufox MD. PET imaging in oncology. Semin Nucl Med 2000; 30: 150-185.
30. Paul R. Comparison of fluorine-18deoxyglucose and gallium-67 citrate imaging for detection of lymphoma. J Nucl Med 1987; 28: 288-292.
31. Okada J, Yoshikawa K, Imazeki K et al. The use of FDG-PET in the detection and management of malignant lymphoma: Correlation of uptake with prognosis. J Nucl Med 1991; 32: 686-691.
32. La-pela M, Leskinen S, Minn HRI et al. Increase glucose metabolism in untreated non-Hodgkin's lymphoma: A study with positron emission tomography and fluorine-18deoxyglucose. Blood 1995; 86: 3522-3527.
33. Leskinen-Kallio S, Ruotsalainen U, Nagren K et al. Uptake of carbon-11-methionine and fluorodeoxyglucose in non-Hodgkin's lymphoma: A PET study. J Nucl Med 1991; 32: 1211-1218.
34. Rodriguez M, Rhen S, Ahlstrom H et al. Predicting malignancy grade with PET in non-Hodgkin's lymphoma. J Nucl Med 1995; 36: 1790-1796.
35. Jerusalem G, Warland V, Majjar F et al. Whole body 18FFDG-PET for the evaluation of patients with Hodgkin's disease and non-Hodgkin's lymphoma. Nucl Med Commun 1999; 20: 13-20.
36. Valenzuela AA, Allen C, Grimes D, Wong D, Sullivan TJ. Positron emission tomography in the detection and staging of ocular adnexal lymphoproliferative disease. Ophthalmology 2006, doi:10.1016/ j.ophtha.2006.05.059.
37. von Schulthess GK. Clinical Molecular Anatomic Imaging - PET, PET/CT and SPECT/CT. Lippincott Williams & Wilkins: Sydney, 2003.
38. Hicks RJ, MacManus MP, Seymour JF. Initial staging of lymphoma with positron emission tomography and computed tomography. Sem Nucl Med 2005; 35: 165-175.
39. Jenkins C, Rose GE, Bunce C, Cree I, Norton A, Plowman PN et al. Clinical features associated with survival of patients with lymphoma of the ocular adnexa. Eye 2003; 17: 809-820.